NCT00154102 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 599
- group Id
- BG001
- value
- 599
- group Id
- BG002
- value
- 1198
- units
- Participants
- groups
- description
- Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
- id
- BG000
- title
- Cetuximab Plus FOLFIRI
- description
- Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
- id
- BG001
- title
- FOLFIRI Alone
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.52
- value
- 60.0
- group Id
- BG001
- spread
- 11.06
- value
- 59.8
- group Id
- BG002
- spread
- 10.79
- value
- 59.9
- description
- Age missing for 1 subject
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Missing
- categories
- measurements
- group Id
- BG000
- value
- 374
- group Id
- BG001
- value
- 377
- group Id
- BG002
- value
- 751
- title
- Between 18 and 65 years
- categories
- measurements
- group Id
- BG000
- value
- 224
- group Id
- BG001
- value
- 222
- group Id
- BG002
- value
- 446
- title
- >=65 years
- description
- Age missing for 1 subject
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 230
- group Id
- BG001
- value
- 243
- group Id
- BG002
- value
- 473
- title
- Female
- measurements
- group Id
- BG000
- value
- 369
- group Id
- BG001
- value
- 356
- group Id
- BG002
- value
- 725
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Gender
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 262
- group Id
- BG001
- value
- 267
- group Id
- BG002
- value
- 529
- title
- Western Europe
- categories
- measurements
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 201
- group Id
- BG002
- value
- 404
- title
- Eastern Europe
- categories
- measurements
- group Id
- BG000
- value
- 134
- group Id
- BG001
- value
- 131
- group Id
- BG002
- value
- 265
- title
- Rest of the World
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 599
- group Id
- BG001
- value
- 599
- group Id
- BG002
- value
- 1198
- units
- Participants
- groups
- description
- Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
- id
- BG000
- title
- Cetuximab Plus FOLFIRI
- description
- Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
- id
- BG001
- title
- FOLFIRI Alone
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.52
- value
- 60.0
- group Id
- BG001
- spread
- 11.06
- value
- 59.8
- group Id
- BG002
- spread
- 10.79
- value
- 59.9
- description
- Age missing for 1 subject
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Missing
- categories
- measurements
- group Id
- BG000
- value
- 374
- group Id
- BG001
- value
- 377
- group Id
- BG002
- value
- 751
- title
- Between 18 and 65 years
- categories
- measurements
- group Id
- BG000
- value
- 224
- group Id
- BG001
- value
- 222
- group Id
- BG002
- value
- 446
- title
- >=65 years
- description
- Age missing for 1 subject
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 230
- group Id
- BG001
- value
- 243
- group Id
- BG002
- value
- 473
- title
- Female
- measurements
- group Id
- BG000
- value
- 369
- group Id
- BG001
- value
- 356
- group Id
- BG002
- value
- 725
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Gender
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 262
- group Id
- BG001
- value
- 267
- group Id
- BG002
- value
- 529
- title
- Western Europe
- categories
- measurements
- group Id
- BG000
- value
- 203
- group Id
- BG001
- value
- 201
- group Id
- BG002
- value
- 404
- title
- Eastern Europe
- categories
- measurements
- group Id
- BG000
- value
- 134
- group Id
- BG001
- value
- 131
- group Id
- BG002
- value
- 265
- title
- Rest of the World
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Independent clinical review pending · Not medical advice
Triangle